IP Library Patent Application 11459144
Patent Application
App. No. 11/459,144

IN-SOLUTION ACTIVATION OF FACTOR VII

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/459,144
Abstract

The present invention is directed to a method for activation of Factor VII to FVIIa in solution.

Claims (18)

1 . A method for activating FVII to FVIIa in solution, comprising

(a) obtaining a solution comprising a substantially purified preparation of scFVII;

(b) adding to the solution an amine compound, Ca 2+ to a final concentration of about 2 mM to about 50 mM, and adjusting the final pH of the solution to about pH 7.2 to 8.6;

(c) incubating the resulting activation mixture at between about 2° C. and about 25° C. for an amount of time sufficient to convert at least 90% of the scFVII to FVIIa; and

(d) optionally, isolating the FVIIa from the activation mixture.

2 . The method of claim 1 wherein the solution comprising the substantially purified preparation of scFVII contains at least 85% scFVII relative to FVIIa or other FVII-derived fragments.

3 . The method of claim 1 wherein the amine compound is Tris, lysine, arginine, phosphorylcholine, or betaine.

4 . The method of claim 1 wherein the amine compound is added to a final concentration of about 50 mM to about 500 mM.

5 . The method of claim 1 wherein the final pH of the solution is pH 7.6 to 8.2

6 . The method of claim 5 wherein the final pH of the solution is about pH 8.

7 . The method of claim 1 wherein the activation mixture has an initial concentration of scFVII of at least 4 mg/ml.

8 . The method of claim 1 wherein the activation mixture has an initial concentration of scFVII of about 1 mg/ml to 4 mg/ml, and the activation mixture further comprises an activation enhancer.

9 . The method of claim 8 wherein the activation enhancer is polyethylene glycol, glycerol, or ethylene glycol.

10 . The method of claim 9 wherein the activation enhancer is PEG4000, PEG8000, or glycerol.

11 . The method of claim 1 wherein the amount of time sufficient to convert at least 90% of the scFVII to FVIIa is between about 4 hours and 24 hours.

12 . The method of claim 1 wherein the activation mixture has an initial concentration of scFVII of about 4 mg/ml to about 10 mg/ml, the amine compound is Tris or lysine at a final concentration of about 0.1 M, the Ca 2+ concentration is 10 mM to 30 mM, the pH of the activation mixture is about pH 8, and the solution is incubated at about 4° C. for 8-24 hrs.

13 . The method of claim 1 wherein the FVII is a FVII variant which differs in 1-15 amino acid residues from the amino acid sequence of human FVII (SEQ ID NO:1).

14 . The method of claim 13 wherein the FVII variant comprises the substitutions P10Q and K32E.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2008
From: MAXYGEN HOLDINGS LTD.
To: BAYER HEALTHCARE LLC
Reel/Frame 021450/0225 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2007
From: KREBBER, CLAUS M.; VISWANATHAN, SRIDHAR
To: MAXYGEN, INC.
Reel/Frame 018880/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 12, 2007
From: MAXYGEN, INC.
To: MAXYGEN HOLDINGS LTD.
Reel/Frame 018882/0031 →